신풍제약

019170KOSPI의약품 제조업

47.3 / 100

Reference Date: 2026-07-24

Financial Score15.0 / 40

News Sentiment16.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly down 4.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Shinpoong Pharmaceutical is enhancing its competitiveness in the highly competitive domestic pharmaceutical market through global new drug development, improved generics, and first-generic launches, while focusing investments on high-profit products to improve profitability. Although sales increased by approximately 10.42% compared to the previous period, the company still recorded an operating loss due to ongoing R&D expenses.

Number of Employees

792people

Average Salary

77.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

49.36Industry Average 11.230.0Point

4.4x industry avg (risky)

PBR

1.53Industry Average 0.811.0Point

1.9x industry avg (risky)

ROE

3.17Industry Average 4.012.5Point

Below industry avg

Debt Ratio

5.48Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.3% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲113.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.2% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 1Average Sentiment Score 65

Negative
K-바이오 신약 3상 잔혹사, 상업화 높은벽 '성장통'
신풍제약 관련 바이오 신약의 임상 실패로 인해 성장에 어려움이 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 7,900Won52-week high 15,69052-week low 7,610

1-month return2.0Point

1m -4.59% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0